The impact of a two- versus three-yearly cervical screening interval recommendation on cervical cancer incidence and mortality: an analysis of trends in Australia, New Zealand, and England

[1]  J. Wise.  Pilot study will assess whether HPV test should replace smears to screen for cervical cancer , 2012, BMJ : British Medical Journal.

[2]  S. Leeson,et al.  Cervical cancer incidence in young women: a historical and geographic controlled UK regional population study , 2012, British Journal of Cancer.

[3]  H. Kitchener,et al.  Increasing rates of cervical cancer in young women in England: an analysis of national data 1982–2006 , 2011, British Journal of Cancer.

[4]  J. Peto,et al.  A comparison of HPV DNA testing and liquid based cytology over three rounds of primary cervical screening: extended follow up in the ARTISTIC trial. , 2011, European journal of cancer.

[5]  C. Mathers,et al.  Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008 , 2010, International journal of cancer.

[6]  K. Howard,et al.  Cervical cancer screening in Australia: modelled evaluation of the impact of changing the recommended interval from two to three years , 2010, BMC public health.

[7]  M. Hakama,et al.  Rate of cervical cancer, severe intraepithelial neoplasia, and adenocarcinoma in situ in primary HPV DNA screening with cytology triage: randomised study within organised screening programme , 2010, BMJ : British Medical Journal.

[8]  J. Cuzick,et al.  Efficacy of human papillomavirus testing for the detection of invasive cervical cancers and cervical intraepithelial neoplasia: a randomised controlled trial. , 2010, The Lancet. Oncology.

[9]  Marc Arbyn,et al.  The challenges of organising cervical screening programmes in the 15 old member states of the European Union. , 2009, European journal of cancer.

[10]  G. Ronco,et al.  Description of the national situation of cervical cancer screening in the member states of the European Union. , 2009, European journal of cancer.

[11]  G. Ronco,et al.  Cervical cancer screening policies and coverage in Europe. , 2009, European journal of cancer.

[12]  F. Bray,et al.  Trends of cervical cancer mortality in the member states of the European Union. , 2009, European journal of cancer.

[13]  J. Geddes,et al.  What is a randomised controlled trial? , 2009, Epidemiologia e Psichiatria Sociale.

[14]  Christine J Sturrock,et al.  Cervical screening in Australia 2006-2007 , 2009 .

[15]  R. Legood,et al.  From cost-effectiveness information to decision-making on liquid-based cytology: Mind the gap. , 2009, Health policy.

[16]  B. T. Lin.  Human papillomavirus DNA versus papanicolaou screening tests for cervical cancer. , 2008, The New England journal of medicine.

[17]  J. Berkhof,et al.  Human papillomavirus DNA testing for the detection of cervical intraepithelial neoplasia grade 3 and cancer: 5-year follow-up of a randomised controlled implementation trial , 2007, The Lancet.

[18]  V. Beral,et al.  Cervical cancer and hormonal contraceptives: collaborative reanalysis of individual data for 16 573 women with cervical cancer and 35 509 women without cervical cancer from 24 epidemiological studies , 2007, The Lancet.

[19]  Stephen D Walter,et al.  Human papillomavirus DNA versus Papanicolaou screening tests for cervical cancer. , 2007, The New England journal of medicine.

[20]  J. Berkhof,et al.  Risk of high‐grade cervical intra‐epithelial neoplasia based on cytology and high‐risk HPV testing at baseline and at 6‐months , 2007, International journal of cancer.

[21]  V. Beral,et al.  Cervical cancer in Australia and the United Kingdom: comparison of screening policy and uptake, and cancer incidence and mortality , 2006, The Medical journal of Australia.

[22]  Joakim Dillner,et al.  Cervical carcinoma and reproductive factors: Collaborative reanalysis of individual data on 16,563 women with cervical carcinoma and 33,542 women without cervical carcinoma from 25 epidemiological studies , 2006, International journal of cancer.

[23]  V. Beral,et al.  Carcinoma of the cervix and tobacco smoking: Collaborative reanalysis of individual data on 13,541 women with carcinoma of the cervix and 23,017 women without carcinoma of the cervix from 23 epidemiological studies , 2006, International journal of cancer.

[24]  P. Boyle,et al.  Chapter 11 . Statistical methods for registries , 2006 .

[25]  Richard J. K. Taylor,et al.  Decline in Cervical Cancer Incidence and Mortality in New South Wales in Relation to Control Activities (Australia) , 2006, Cancer Causes & Control.

[26]  J. Cuzick,et al.  Benefit of cervical screening at different ages: evidence from the UK audit of screening histories , 2003, British Journal of Cancer.

[27]  R. Taylor,et al.  Effects of screening on cervical cancer incidence and mortality in New South Wales implied by influences of period of diagnosis and birth cohort , 2001, Journal of epidemiology and community health.

[28]  J. Patnick.  Cervical cancer screening in England. , 2000, European journal of cancer.

[29]  P. Edwards,et al.  British Medical Journal , 1876 .

[30]  O. M. Jensen,et al.  Cancer Registration: Principles and Methods , 1991 .

[31]  D. Slater,et al.  National cervical screening programme. , 1990, BMJ.

[32]  Screening for squamous cervical cancer: duration of low risk after negative results of cervical cytology and its implication for screening policies. IARC Working Group on evaluation of cervical cancer screening programmes. , 1986, British medical journal.

[33]  M. Plummer,et al.  International agency for research on cancer. , 2020, Archives of pathology.

[34]  J. Ferlay,et al.  Cancer Incidence in Five Continents , 1970, Union Internationale Contre Le Cancer / International Union against Cancer.